Fred A. Middleton
- Mr. Middleton is a Managing Director of Mesa Verde and Chairman of the Investment Committee. Mr. Middleton has over 30 years experience in the biotechnology and biomedical industries in both corporate operating management and as an institutional venture capital investor. He has played an active role as Chairman, CEO or Director of over 25 new biomedical ventures including Regeneron Pharmaceuticals(NASDAQ:REGN) ViaCyte, CardioNet (NASDAQ: BEAT), Endocyte (ECYT), Pacira Pharmaceuticals (NASDAQ:PCRX) and Lineagen, Inc (A Mesa Verde I Investment). In 1978 he was the founding CFO of Genentech. While at Genentech Mr. Middleton successfully completed over $200 million in corporate partnering and institutional funding transactions, including managing the company's successful IPO in 1980. Subsequent to Genentech, Mr. Middleton founded Morgan Stanley Ventures in 1984. In 1987, he joined Sanderling and has been instrumental in transforming Sanderling into a top tier Life Science VC firm with over $1 billion in capital under management today with over 95 biomedical investments. Mr. Middleton has worked with Mesa Verde Ventures since 2007 and made a $5 Million investment on the behalf of Sanderling Ventures. He has also served as a member of the Board of Trustees for M.I.T. and as an Advisory Council Member to the Koch Institute for Integrative Cancer Research at M.I.T. Mr. Middleton holds a B.S. from MIT in Chemistry, an MBA from the Harvard Business School and was also a consultant at McKinsey & Co. prior to his founding role at Genentech.